Guardant Health, Inc. has entered into a multi-year strategic collaboration with Merck, also known as MSD outside the United States and Canada, to develop companion diagnostics and commercialize new cancer therapies. This collaboration, announced on January 19, 2026, will leverage the Guardant Infinity™ Smart platform to enhance Merck’s oncology portfolio.
Collaboration Aims to Enhance Cancer Care
Under the terms of the agreement, the two companies will work together to improve the precision of cancer therapies through advanced biomarker analysis. Helmy Eltoukhy, chairman and co-CEO of Guardant Health, emphasized the significance of this partnership, stating, “This strategic collaboration allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today.”
As cancer treatment increasingly relies on biomarker data for therapy selection, the collaboration aims to ensure that clinical trials are equipped with the necessary molecular insights to identify suitable patients. Eltoukhy noted that this partnership strengthens both companies’ commitment to rigor, scale, and the accelerated development of transformative cancer treatments.
About Guardant Health
Founded in 2012 and based in Palo Alto, California, Guardant Health is renowned for its role in precision oncology. The company is dedicated to improving patient outcomes by providing essential insights into cancer through advanced blood and tissue testing, real-world data, and artificial intelligence analytics.
Guardant’s diagnostic tests are designed to assist healthcare providers in various stages of cancer care, from early detection through screening to treatment selection for patients with advanced cancer. Their innovative approaches aim to identify cancer sooner and monitor recurrence effectively, thus enhancing the overall patient experience.
As the collaboration progresses, both Guardant Health and Merck are set to play a crucial role in the evolution of cancer diagnostics and treatment, potentially impacting the lives of countless patients worldwide.
For further information about Guardant Health and their initiatives, visit their official website or connect with them on social media platforms.
“This collaboration strengthens our shared commitment to rigor, scale, and faster development of life-changing cancer therapies.” – Helmy Eltoukhy
Investors and media can reach out for inquiries regarding this partnership through the provided contact information on Guardant Health’s website.
